Literature DB >> 1600592

Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

W Kreis1, M Lesser, D R Budman, Z Arlin, L DeAngelis, P Baskind, E J Feldman, S Akerman.   

Abstract

Two phenotypes for 1-B-D-arabinofuranosylcytosine (ara-C) deamination corresponding to a ratio of distribution for "slow" (ratio, less than or equal to 14) vs "fast" (ratio, greater than 14) deaminators of 70%:30%, have been determined on the basis of studies on plasma ratios of 1-B-D-arabinofuranosyluracil/ara-C (ara-U/ara-C) in 56 subjects treated with high-dose ara-C (3 g/m2 infused i.v. over 3 h). A positive correlation of age with the concentration of ara-U was observed. In a subgroup of 36 patients with leukemia, the ara-U/ara-C pattern was similar to that observed for all 56 subjects. In these leukemic patients, who were treated with combinations of ara-C plus other conventional agents, a tendency toward a positive response (complete response + partial response) was found for those showing low ara-U/ara-C ratios (slow deaminators). The phenotypic effect of deamination in acute leukemia needs to be evaluated prospectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600592     DOI: 10.1007/bf00686404

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.

Authors:  C N Coleman; D G Johns; B A Chabner
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

2.  Detection after electrophoresis of enzymes involved in ammonia metabolism using L-glutamate dehydrogenase as a linking enzyme.

Authors:  R L Nelson; S Povey; D A Hopkinson; H Harris
Journal:  Biochem Genet       Date:  1977-12       Impact factor: 1.890

3.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity.

Authors:  G W Camiener; C G Smith
Journal:  Biochem Pharmacol       Date:  1965-10       Impact factor: 5.858

4.  Cytidine deaminase and the development of resistance to arabinosyl cytosine.

Authors:  C D Steuart; P J Burke
Journal:  Nat New Biol       Date:  1971-09-22

Review 5.  High dose cytarabine: a review.

Authors:  B J Bolwell; P A Cassileth; R P Gale
Journal:  Leukemia       Date:  1988-05       Impact factor: 11.528

6.  Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

Authors:  Y M Rustum; H D Preisler
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

7.  The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.

Authors:  A L Harris; D G Grahame-Smith
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Metabolism of 1-beta-D-arabinofuranosyluracil in mouse L5178Y cells.

Authors:  W E Müller; R K Zahn
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

9.  Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.

Authors:  Y M Rustum; H K Slocum; G Wang; D Bakshi; E Kelly; D Buscaglia; C Wrzosek; A P Early; H Preisler
Journal:  Med Pediatr Oncol       Date:  1982

10.  Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.

Authors:  J L Yang; E H Cheng; R L Capizzi; Y C Cheng; T Kute
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more
  5 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

3.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

Review 4.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Modulation of the effect of 1-beta-D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells.

Authors:  Y Kawai; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1994-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.